TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02080624
Drug: Drug: Topical Rapamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment.
Study: NCT00345644
Drug: risedronate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for risedronate tablets (once a week dose)
Study: NCT00328302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03820830
Drug: Standard endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
Study: NCT03562923
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
Study: NCT03562923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Product
Study: NCT00395343
Drug: Comparator : placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
Study: NCT02842554
Drug: Drug Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00966875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous
Study: NCT00689117
Drug: Clindamycin Gel (clindamycin )
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
Study: NCT00689117
Drug: Tretinoin Gel (tretinoin)
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
Study: NCT00689117
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
Study: NCT00970385
Drug: CHOP21
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5.
Study: NCT00970385
Drug: VIP/ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D
Study: NCT03706547
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT01048411
Drug: Naja-comp.
Approvals — FDA: no, EMA: no, PMDA: no
Description: homeopathic remedy
Study: NCT01048411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection of NaCl-solution three times a week
Study: NCT03170271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
Study: NCT04395053
Drug: SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.
Study: NCT00511394
Drug: 20% Human Albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 100 mL of 20% Albumin over 3 hours
Study: NCT00511394
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 100 mL of Normal Saline
Study: NCT00712400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Study: NCT03503513
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
Study: NCT01170039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched placebo pill will be given twice a day for 8 weeks.
Study: NCT03400267
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Study: NCT01906801
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03112954
Drug: Buccal-relaxant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
Study: NCT03112954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
Study: NCT02299739
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
Study: NCT04166331
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
Study: NCT03635021
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
Study: NCT03635021
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
Study: NCT00637949
Drug: rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg, oral, daily over 6 weeks
Study: NCT00935415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules of matching placebo
Study: NCT03660059
Drug: Plaebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01797809
Drug: EV/DNG (Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
Study: NCT04034251
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
Study: NCT02739633
Drug: Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Study: NCT01258569
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
Study: NCT04263584
Drug: R-CHOP Chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy
Study: NCT01267227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo by mouth twice daily for 6 to 8 weeks
Study: NCT03745599
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study: NCT03745599
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study: NCT03236155
Drug: opioid pain pills
Normalized name: Arthriten Inflammatory Pain Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient will receive their pain pill prescription
Study: NCT02561767
Drug: Induction therapy (ATG or Basiliximab)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
Study: NCT02561767
Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Study: NCT01643785
Drug: Second-line quadruple therapy with endonase
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare Second-line quadruple therapy w/o pronase (endonase)
Study: NCT02366364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of placebo consumption on Day 1
Study: NCT02745145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study: NCT01208753
Drug: GLPG0555
Approvals — FDA: no, EMA: no, PMDA: no
Description: two different aqueous formulations
Study: NCT01208753
Drug: GLPG0555 aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
Study: NCT01356290
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-400mg, oral bid, daily, 1 year
Study: NCT01356290
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
Study: NCT01208753
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Study: NCT04367051
Drug: Withdrawal of Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
Study: NCT04367051
Drug: Continuation of spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
Study: NCT00714025
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10mg, daily, PO
Study: NCT00568464
Drug: VCR, CTX, ADM; IFO, VP-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
Study: NCT00275132
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo PO daily
Study: NCT02844062
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 d1-3
Study: NCT03595618
Drug: GLPG1972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of GLPG1972 for oral use.
Study: NCT03595618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of matching placebo for oral use.
Study: NCT04589624
Drug: Hyperpolarized Carbon C 13 Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01269671
Drug: Melatonin, Peppermint Oil (mentharil), and Simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
Study: NCT03332212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Weeks
Study: NCT01410344
Drug: Cyclophosphamide and Total Body Irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.
Study: NCT01980589
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT01912391
Drug: Placebo (for Selegiline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
Study: NCT04874701
Drug: Capsimax
Normalized name: Capsinac KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
Study: NCT03361540
Drug: ASP8302
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8302 will be administered orally.
Study: NCT03361540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT04801264
Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT03708887
Drug: Low dose omega-3 fatty acid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
Study: NCT03708887
Drug: High dose omega-3 fatty acid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Study: NCT03708887
Drug: Control drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules,3 g/d by mouth for 1 year
Study: NCT01552798
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
Study: NCT01552798
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
Study: NCT01552798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Study: NCT03294577
Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT00260364
Drug: Capecitabine orally days 1 -21
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03948477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT04600271
Drug: Colloid Blood Volume Expanders
Normalized name: BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure
Study: NCT04600271
Drug: Diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure
Study: NCT04600271
Drug: Non-Steroidal Anti-Inflammatory Analgesics
Normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure
Study: NCT04993339
Drug: OOC
Normalized name: isooctane
Approvals — FDA: no, EMA: no, PMDA: no
Description: The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
Study: NCT01009892
Drug: Codeine Sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT00552747
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules placebo
Study: NCT02992197
Drug: Placebo (for Rotarix dose 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water to provide volume equivalent as a second dose of Rotarix
Study: NCT01692470
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
Study: NCT03932825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
Study: NCT04121611
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose
Study: NCT02078856
Drug: A3384
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02055638
Drug: SRX246
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT02055638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02527772
Drug: Liposomal Doxorubicin+Gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
Study: NCT02527772
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.